Effect of Colesevelam Hydrochloride on Glycemia and Insulin Sensitivity in Men With the Metabolic Syndrome

Colesevelam hydrochloride (colesevelam) lowers low-density lipoprotein (LDL) cholesterol and glycated hemoglobin in patients with type 2 diabetes mellitus. The present study examined the effects of colesevelam treatment in nondiabetic men with metabolic syndrome. Twenty men completed the study, whic...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2011-10, Vol.108 (8), p.1129-1135
Main Authors: Vega, Gloria Lena, PhD, Dunn, Fredrick L., MD, Grundy, Scott M., MD, PhD
Format: Article
Language:English
Subjects:
Adult
Aged
Allylamine - administration & dosage
Allylamine - analogs & derivatives
Allylamine - therapeutic use
Anticholesteremic Agents - administration & dosage
Anticholesteremic Agents - therapeutic use
Biological and medical sciences
Blood Glucose - metabolism
Cardiology. Vascular system
Cardiovascular
Colesevelam Hydrochloride
Cross-Over Studies
Diabetes
Dose-Response Relationship, Drug
Double-Blind Method
Follow-Up Studies
Glucose Tolerance Test
Hemoglobin
Humans
Hyperglycemia - blood
Hyperglycemia - etiology
Hyperglycemia - prevention & control
Insulin - blood
Insulin Resistance - physiology
Lipids - blood
Low density lipoprotein
Male
Medical sciences
Medical treatment
Metabolic diseases
Metabolic syndrome
Metabolic Syndrome - blood
Metabolic Syndrome - complications
Metabolic Syndrome - drug therapy
Middle Aged
Miscellaneous
Other metabolic disorders
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colesevelam hydrochloride (colesevelam) lowers low-density lipoprotein (LDL) cholesterol and glycated hemoglobin in patients with type 2 diabetes mellitus. The present study examined the effects of colesevelam treatment in nondiabetic men with metabolic syndrome. Twenty men completed the study, which consisted of two 8-week phases of treatment with colesevelam (3.75 g/day) or placebo and a 6-week washout between study phases. Of the 20 men, 17 took statins throughout. The fasting plasma LDL cholesterol, triglyceride, glucose, and glycated hemoglobin levels were measured in the last 2 weeks of each study phase. Nonesterified fatty acids and 3-hydroxybutyrate, insulin, and glucose were measured hourly for 5 hours during fasting and during an extended glucose tolerance test. The colesevelam treatment reduced LDL cholesterol from 96 ± 28 mg/dl to 78 ± 32 mg/dl (p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2011.06.011